News & Updates
Showing Pharmacy articles
Showing
ADHD medication use carries no excess cardiovascular disease risk
Attention-deficit/hyperactivity disorder (ADHD) medications do not appear to put users at increased risk of cardiovascular disease (CVD), although a modest risk increase for cardiac arrest or tachyarrhythmias cannot be ruled out, according to the results of a meta-analysis.
IV antihypertensives up myocardial injury risk in hospitalized patients with severe hypertension
Use of intravenous (IV) antihypertensive treatment appears to increase the risk of myocardial injury in patients who develop severe hypertension during hospitalization and without acute target end organ damage, reveals a recent study.
Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC
Updated results of the DESTINY-Breast03 trial, presented at SABCS 2022, showed that in patients with HER2+ metastatic breast cancer, second-line treatment with trastuzumab deruxtecan conferred better survival benefits than treatment with trastuzumab emtansine.
TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients
Tumour necrosis factor (TNF)-α antagonists show comparable safety as non-TNF biologics in the treatment of inflammatory bowel disease (IBD) in patients with active or recent cancer, as shown in a study.
Can RA patients taper MTX from targeted therapy?
A recent study has found that tapering methotrexate (MTX) from targeted therapy in patients with controlled rheumatoid arthritis (RA) is feasible, but this may result in a 10-percent decrease in the ability to sustain remission for up to 18 months.